Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morten Andersen

Showing results (1-10 of 197) with videos related to

Pageof 20
Sort By:
Basic & Clinical Pharmacology & Toxicology|April 14, 2006
Is it possible to measure prescribing quality using only prescription data?Morten Andersen
Ugeskrift for Laeger|March 16, 2002
[Blue "marmoration" of legs as an adverse effect of vaccination]Morten Andersen
Pharmacoepidemiology and Drug Safety|November 21, 2021
Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrel-An observational cohort study in SwedenMarie Linder, Morten Andersen
Basic & Clinical Pharmacology & Toxicology|April 14, 2006
Current controversies in pharmacoepidemiologyJesper Hallas, Morten Andersen
Ugeskrift for Laeger|January 24, 2008
[Non-compliance--need of an evidence-based action]Morten Andersen, Jens Søndergaard
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 20, 2021
New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System DatabaseMaurizio Sessa, Morten Andersen
Cancers|August 7, 2021
Potential of Immunotherapies in Treating Hematological Cancer-Infection Comorbidities-A Mathematical Modelling ApproachJohnny T Ottesen, Morten Andersen
Cancers|October 14, 2023
Aging, Inflammation, and Comorbidity in Cancers-A General In Silico Study Exemplified by Myeloproliferative MalignanciesJohnny T Ottesen, Morten Andersen
European Journal of Clinical Pharmacology|June 20, 2006
Narrow and wide prescribers among general practitioners: a cohort study of drug formularies used for new treatmentsAllan Buusman, Jakob Kragstrup, Morten Andersen
Ugeskrift for Laeger|March 7, 2009
[Drug utilization research--indications should be well documented for all kind of users]Jens Søndergaard, Lars Bjerrum, Morten Andersen
Pageof 20

Showing results (1-10 of 197) with videos related to

Sort By:
Pageof 20
Basic & Clinical Pharmacology & Toxicology|April 14, 2006
Is it possible to measure prescribing quality using only prescription data?Morten Andersen
Ugeskrift for Laeger|March 16, 2002
[Blue "marmoration" of legs as an adverse effect of vaccination]Morten Andersen
Pharmacoepidemiology and Drug Safety|November 21, 2021
Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrel-An observational cohort study in SwedenMarie Linder, Morten Andersen
Basic & Clinical Pharmacology & Toxicology|April 14, 2006
Current controversies in pharmacoepidemiologyJesper Hallas, Morten Andersen
Ugeskrift for Laeger|January 24, 2008
[Non-compliance--need of an evidence-based action]Morten Andersen, Jens Søndergaard
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 20, 2021
New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System DatabaseMaurizio Sessa, Morten Andersen
Cancers|August 7, 2021
Potential of Immunotherapies in Treating Hematological Cancer-Infection Comorbidities-A Mathematical Modelling ApproachJohnny T Ottesen, Morten Andersen
Cancers|October 14, 2023
Aging, Inflammation, and Comorbidity in Cancers-A General In Silico Study Exemplified by Myeloproliferative MalignanciesJohnny T Ottesen, Morten Andersen
European Journal of Clinical Pharmacology|June 20, 2006
Narrow and wide prescribers among general practitioners: a cohort study of drug formularies used for new treatmentsAllan Buusman, Jakob Kragstrup, Morten Andersen
Ugeskrift for Laeger|March 7, 2009
[Drug utilization research--indications should be well documented for all kind of users]Jens Søndergaard, Lars Bjerrum, Morten Andersen
Pageof 20